“…Early experience of MRIgRT includes a proportion of patients treated for prostate cancer in most mixed tumor series (Bertelsen et al , 2019; Henke et al , 2018; Sahin et al , 2019). Although many start with moderately hypofractionated regimens, the resource intensity of MRIgRT makes extreme hypofractionation attractive from a resource, as well as a radiobiological, perspective in prostate cancer (Hall et al , 2022).…”